• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NewGenIvf Group Limited

    11/10/25 4:00:19 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email
    6-K 1 ea0264745-6k_newgenivf.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

     

    Commission File Number: 001-42004

     

    NEWGENIVF GROUP LIMITED

     

    36/39-36/40, 13th Floor, PS Tower

    Sukhumvit 21 Road (Asoke)

    Khlong Toei Nuea Sub-district

    Watthana District, Bangkok 10110

    Thailand

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒        Form 40-F ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On November 4, 2025, the Board of Directors of NewGenIvf Group Limited (the “Company”) approved a reverse stock split of all of the Company’s issued and unissued shares, including the Class A ordinary shares with no par value (the “Class A Ordinary Shares”), Class B ordinary shares with no par value and preferred shares with no par value, at an exchange ratio of one (1) share for five (5) shares (the “Reverse Stock Split”). Pursuant to the BVI Business Companies Act (as amended) and the Company’s M&A, the Company’s Board of Directors is authorized to effect the Reverse Share Split without the approval of the Company’s shareholders. Accordingly, no shareholder vote, consent or approval is required or will be sought in respect of the Reverse Share Split. The Company expects that the Reverse Stock Split will become effective on or around December 3, 2025, and that its Class A Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-Reverse Stock Split basis on such date.

     

    The Reverse Stock Split is intended for the Company to remain compliant with a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).

     

    The Reverse Stock Split will reduce the number of outstanding Class A Ordinary Shares of the Company from approximately 4,844,490 to approximately 968,898 Class A Ordinary Shares. Every five (5) outstanding Class A Ordinary Shares will be combined into and automatically become one post-Reverse Stock Split Class A Ordinary Share. No fractional shares will be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.

     

    After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other convertible securities are exercisable or convertible by five (5) in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.

     

    No amendment to the Company’s M&A will be required to be made in relation to the Reverse Share Split, as (i) the Reverse Share Split will have no effect upon the par value of the ordinary shares, which is currently nil and will remain at nil after the Reverse Share Split is effected, and (ii) the number of shares authorized to be issued under the Company’s M&A is unlimited and therefore will not be affected by the Reverse Share Split.

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: November 10, 2025

     

      NewGenIvf Group Limited
         
      By: /s/ Wing Fung Alfred Siu
      Name:  Wing Fung Alfred Siu
      Title: Chairman of the Board and Director

     

    2

     

    Get the next $NIVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    12/2/25 8:01:34 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    11/25/25 4:00:29 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    11/10/25 4:00:19 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen to Exercise Option to Convert Ras Al Khaimah Joint Venture into Joint Development, Projected to Boost Profits from US$67 Million to US$123 Million

    BANGKOK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced its intention to exercise an option under its joint venture agreement ("JVA") with BNW Real Estate Development LLC ("BNW") to convert the Ras Al Khaimah development project from a Joint Venture structure into a Joint Development structure, while maintaining the existing shareholding of the special purpose vehicle ("SPV"). This strategic conversion is expected to enhance NewGen's profit entitlement in the flagship Ras Al Khaimah Beach

    12/12/25 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

    BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or "the Company"), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025. Financial Highlights for the Nine Months Ended September 30, 2025 Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This was primarily due to a non-cash, bargain purchase gain recognized on the acquisition of Nodexus and Microsort businesses.Basic

    12/2/25 8:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Announces Up to US$2 Million Share Repurchase Program

    BANGKOK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its Board of Directors (the "Board") has authorized a share repurchase program under which the Company may repurchase up to US$2 million of its outstanding Class A ordinary shares over the next 24 months ("Share Repurchase Program"). The Company plans to adopt and implement this Share Repurchase Program in accordance with applicable rules and requirem

    11/10/25 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care